DGX's Haystack Oncology Teams Up With Rutgers Cancer Institute

Quest Diagnostics (DGX) subsidiary, Haystack Oncology, announced a research collaboration with Rutgers Cancer Institute for a prospective phase II study evaluating its highly sensitive Haystack MRD (minimal residual disease) test, which utilizes circulating tumor DNA (ctDNA), to guide postoperative therapy decisions in stage II/III non-small cell lung cancer patients. This partnership underscores DGX's strategic positioning within the expanding global MRD market, valued at $2.50 billion in 2024 and projected to grow at a 10.1% CAGR through 2030, leveraging diagnostic advancements and building on its prior FDA Breakthrough Device Designation for colorectal cancer.

Analysis

Quest Diagnostics (DGX) is strategically solidifying its position in the high-growth oncology diagnostics market through its Haystack Oncology subsidiary. The newly announced research collaboration with the Rutgers Cancer Institute for a phase II trial (NCT06979661) will evaluate its Haystack MRD test's ability to guide postoperative therapy in non-small cell lung cancer, a significant clinical application. This initiative builds on existing momentum, including a previous Rutgers study for breast cancer and a 2025 FDA Breakthrough Device Designation for its use in colorectal cancer, demonstrating a clear strategy of building clinical evidence to drive adoption. This positions DGX to capture a share of the global minimal residual disease (MRD) market, which was valued at $2.50 billion in 2024 and is projected to grow at a 10.1% compound annual growth rate through 2030. However, the competitive landscape is intense, with peers like QIAGEN (QGEN), Exact Sciences (EXAS), and Guardant Health (GH) also achieving significant milestones, including new product launches, regulatory clearances, and strategic partnerships. The advancements by competitors, such as EXAS's launch of the Cancerguard test and GH securing Breakthrough Device Designation for its Shield test, underscore the rapid pace of innovation and the fight for market share in the broader cancer diagnostics space.

Key Decisions for Investors

• Investors in Quest Diagnostics should view the Rutgers collaboration as a significant de-risking event for its Haystack MRD asset, providing a clear clinical validation pathway in the lucrative lung cancer market.
• It is crucial to monitor the competitive advancements from peers like Exact Sciences and Guardant Health, as their progress in multi-cancer early detection and securing regulatory wins could impact DGX's long-term market share and pricing power in the diagnostics sector.
• Given the sustained innovation and favorable market growth projected at a 10.1% CAGR, investors may consider increasing exposure to the cancer diagnostics sub-sector, while closely tracking clinical trial data and commercialization progress for DGX and its key competitors to identify emerging leaders.